TNFSF11 Antibody

What is TNFSF11 and what are its alternative names in scientific literature?

TNFSF11 (Tumor necrosis factor ligand superfamily member 11) is known by several alternative names in scientific literature, including RANKL (Receptor activator of nuclear factor kappa-B ligand), TRANCE (TNF-related activation-induced cytokine), OPGL (Osteoprotegerin ligand), ODF (Osteoclast differentiation factor), and CD254. This 317-amino acid protein is encoded by the TNFSF11 gene and belongs to the tumor necrosis factor (TNF) cytokine family . When designing experiments or searching literature, researchers should use multiple search terms to ensure comprehensive coverage of relevant studies.

What are the key biological functions of TNFSF11 protein?

TNFSF11 functions as a critical cytokine that binds to TNFRSF11B (osteoprotegerin) and TNFRSF11A (RANK). Its primary biological roles include:

• Osteoclast differentiation and activation factor

• Enhancement of dendritic cell ability to stimulate naive T-cell proliferation

• Regulation of interactions between T-cells and dendritic cells

• Modulation of T-cell-dependent immune responses

• Bone resorption in pathological conditions like humoral hypercalcemia of malignancy

Mechanistically, TNFSF11 induces osteoclastogenesis by activating multiple signaling pathways in osteoclast precursor cells. A key mechanism involves the induction of sustained oscillations in intracellular Ca²⁺ concentration, leading to NFATC1 activation, nuclear translocation, and subsequent transcription of osteoclast-specific genes .

What is the molecular structure of TNFSF11 and how does it exist in biological systems?

TNFSF11 exists in two primary forms:

• Membrane-bound form (mRANKL): approximately 40-45 kDa

• Soluble form (sRANKL): approximately 31 kDa

The membrane-bound form can be cleaved into the soluble form by metalloprotease-disintegrin TNF-alpha convertase (TACE) or related metalloproteases . The protein has a calculated molecular weight of 20.5 kDa but typically migrates as a 28-33 kDa protein on SDS-PAGE due to glycosylation . This discrepancy between theoretical and observed molecular weights is important for researchers to consider when interpreting western blot results.

What criteria should researchers use when selecting an appropriate TNFSF11 antibody for their experiments?

When selecting a TNFSF11 antibody, researchers should consider:

• Target specificity: Verify the antibody recognizes the specific epitope of interest within TNFSF11

• Species reactivity: Confirm reactivity with the species being studied (human, mouse, rat)

• Antibody type: Determine whether polyclonal or monoclonal antibodies are more suitable for the application

• Applications validated: Ensure the antibody has been validated for the intended application (WB, IHC, IF, ELISA, flow cytometry)

• Clone information: For monoclonal antibodies, note the clone number (e.g., 685857)

• Form and conjugation: Consider whether unconjugated or conjugated (e.g., PE-conjugated) formats are needed

For applications requiring precise epitope targeting, researchers should select antibodies raised against specific regions of TNFSF11, such as those targeting the C-terminal extracellular region .

How can researchers validate TNFSF11 antibodies before proceeding with experimental applications?

Validation of TNFSF11 antibodies should include:

• Positive and negative controls: Use cell lines known to express TNFSF11 (e.g., Raji cells) as positive controls and appropriate negative controls

• Specificity testing: Perform blocking experiments with recombinant TNFSF11 protein to confirm binding specificity

• Cross-reactivity assessment: Test against related proteins in the TNF superfamily to confirm specificity

• Multiple detection methods: Validate using orthogonal techniques (e.g., western blot and immunofluorescence)

• Reproducibility testing: Ensure consistent results across multiple experiments

A robust validation protocol might include ELISA binding assays where immobilized TNFSF11 protein (2 μg/mL) is tested for binding with known interactors like RANK and Osteoprotegerin to verify functionality .

What dilution ranges are typically effective for different TNFSF11 antibody applications?

Optimal antibody dilutions vary by application and specific antibody preparation:

Important note: These ranges are guidelines only. Each antibody should be titrated in each testing system to obtain optimal results, as the efficiency can be sample-dependent .

What are the recommended protocols for using TNFSF11 antibodies in immunohistochemistry applications?

For optimal immunohistochemistry results with TNFSF11 antibodies:

• Tissue preparation: Use formalin-fixed, paraffin-embedded sections at 4-6 μm thickness

• Antigen retrieval: Perform heat-induced epitope retrieval using TE buffer (pH 9.0) or alternatively citrate buffer (pH 6.0)

• Blocking: Block endogenous peroxidase activity and non-specific binding sites

• Primary antibody incubation: Apply TNFSF11 antibody at 1:50-1:500 dilution (optimized per antibody) and incubate overnight at 4°C

• Detection system: Use appropriate detection system based on host species of primary antibody

• Controls: Include positive controls (human stomach cancer tissue, human colon tissue, human heart tissue) and negative controls

• Counterstaining: Counterstain with hematoxylin for nuclear visualization

The specific antigen retrieval method is critical for TNFSF11 detection and may need optimization depending on tissue type and fixation conditions.

How should researchers set up western blot experiments to detect TNFSF11 protein?

For western blot detection of TNFSF11:

• Sample preparation: Extract proteins using RIPA buffer supplemented with protease inhibitors

• Protein quantification: Determine protein concentration using Bradford or BCA assay

• Gel electrophoresis: Load 20-40 μg protein per lane on 10-12% SDS-PAGE gel

• Transfer: Transfer proteins to PVDF or nitrocellulose membrane

• Blocking: Block membrane with 5% non-fat milk or BSA in TBST for 1 hour

• Primary antibody: Incubate with TNFSF11 antibody (1:500-1:1000 dilution) overnight at 4°C

• Secondary antibody: Apply HRP-conjugated secondary antibody for 1 hour at room temperature

• Detection: Visualize using ECL substrate and imaging system

When interpreting results, note that TNFSF11 typically appears at 20-30 kDa on western blots, though the calculated molecular weight is 35 kDa. This discrepancy is due to glycosylation patterns . Raji cells can serve as positive controls for TNFSF11 expression.

What flow cytometry protocols are effective for detecting TNFSF11 expression in immune cells?

For flow cytometry detection of TNFSF11:

• Cell preparation: Isolate peripheral blood mononuclear cells (PBMCs) and stimulate with PHA if detecting activated cells

• Cell count adjustment: Adjust to 1×10⁶ cells per sample

• Surface staining:

  • Wash cells in flow cytometry buffer (PBS with 1% BSA, 0.1% sodium azide)

  • Block Fc receptors with 10% normal serum

  • Stain with PE-conjugated anti-TNFSF11 antibody (e.g., clone 685857)

  • Co-stain with other markers as needed (e.g., anti-IL-2 Ra APC-conjugated for activated T cells)

• Washing: Wash twice with flow cytometry buffer

• Analysis: Analyze using appropriate flow cytometer with proper compensation controls

For detecting intracellular TNFSF11, add permeabilization and fixation steps using commercial kits before antibody staining.

What are common issues when using TNFSF11 antibodies and how can researchers address them?

Common issues and solutions when working with TNFSF11 antibodies include:

For TNFSF11 specifically, researchers should be aware that the protein exists in both membrane-bound (40-45 kDa) and soluble (31 kDa) forms, which can complicate western blot interpretation . Additionally, glycosylation causes the protein to migrate at 28-33 kDa despite its calculated MW of 20.5 kDa .

How should researchers interpret different molecular weight bands when detecting TNFSF11 by western blot?

When interpreting western blot results for TNFSF11, researchers should consider:

• Expected molecular weights:

  • Calculated MW: 20.5 kDa

  • Observed MW: 28-33 kDa (due to glycosylation)

  • Membrane-bound form: 40-45 kDa

  • Soluble form: 31 kDa

• Multiple bands may represent:

  • Different glycosylation states

  • Membrane-bound versus soluble forms

  • Proteolytic cleavage products

  • Dimeric or oligomeric forms

• Validation approaches:

  • Compare to recombinant TNFSF11 protein control

  • Use multiple antibodies targeting different epitopes

  • Perform deglycosylation treatment to confirm glycosylation effects

  • Verify with known positive control samples (e.g., Raji cells)

What controls are essential when conducting TNFSF11 antibody-based experiments?

Essential controls for TNFSF11 antibody experiments include:

• Positive tissue/cell controls:

  • Raji cells for western blot

  • Human stomach cancer tissue, human colon tissue, or human heart tissue for IHC

  • PHA-stimulated PBMCs for flow cytometry

• Negative controls:

  • Isotype control antibodies (matching the host species and isotype)

  • Secondary antibody-only controls

  • Known TNFSF11-negative samples

• Specificity controls:

  • Blocking with recombinant TNFSF11 protein

  • siRNA knockdown of TNFSF11

  • TNFSF11 knockout samples (when available)

• Technical controls:

  • Loading controls for western blot (e.g., β-actin, GAPDH)

  • Housekeeping gene controls for qPCR

  • Internal staining controls for flow cytometry and IHC

How can TNFSF11 antibodies be used to investigate RANK/RANKL signaling pathways in osteoclastogenesis research?

For investigating RANK/RANKL signaling in osteoclastogenesis:

• Co-immunoprecipitation studies:

  • Use anti-TNFSF11 antibodies to pull down protein complexes

  • Probe for associated proteins such as TRAF6, SRC kinase, and AKT/PKB

  • Assess interactions under different stimulatory conditions

• Signaling pathway analysis:

  • Apply TNFSF11 to osteoclast precursors and use phospho-specific antibodies to track activation of:

    • NF-κB pathway components

    • Ca²⁺ signaling molecules

    • NFATC1 nuclear translocation

    • CREB1 activation

    • Mitochondrial ROS generation pathways

• Functional assays:

  • Use neutralizing TNFSF11 antibodies to block signaling and assess impact on osteoclast formation

  • Combine with TRAP staining and bone resorption assays

  • Compare effects of blocking different epitopes to identify functional domains

This approach enables detailed mapping of the RANKL-induced signaling cascade that leads to osteoclast differentiation and can identify potential intervention points for bone disorders.

What methodological approaches can researchers use to study the role of TNFSF11 in immune cell interactions?

To investigate TNFSF11's role in immune cell interactions:

• Dendritic cell-T cell co-culture systems:

  • Set up co-cultures of dendritic cells with naive T cells

  • Use TNFSF11 blocking antibodies or recombinant TNFSF11

  • Measure T cell proliferation (e.g., CFSE dilution assay)

  • Assess cytokine production profiles

  • Analyze T cell activation markers

• Flow cytometry-based interaction studies:

  • Utilize PE-conjugated TNFSF11 antibodies to identify TNFSF11-expressing cells

  • Perform multi-parameter flow cytometry with markers for:

    • T cell activation (e.g., IL-2 Ra)

    • Dendritic cell maturation

    • Adhesion molecules

    • Intracellular signaling molecules

• In vivo models with antibody intervention:

  • Administer anti-TNFSF11 antibodies in experimental models of immune response

  • Analyze changes in:

    • T cell-dependent antibody responses

    • Germinal center formation

    • Dendritic cell survival and function

    • Regulatory T cell development

These methodological approaches can elucidate TNFSF11's role as "an important regulator of interactions between T-cells and dendritic cells" and its function "in the regulation of the T-cell-dependent immune response" .

How can researchers design experiments to investigate the role of TNFSF11 in pathological conditions like hypercalcemia of malignancy?

To investigate TNFSF11's role in hypercalcemia of malignancy:

• Expression analysis in pathological samples:

  • Use IHC with validated anti-TNFSF11 antibodies on tumor tissue microarrays

  • Quantify TNFSF11 expression levels in malignant versus normal tissues

  • Correlate expression with clinical parameters including serum calcium levels

• In vitro bone resorption models:

  • Culture bone slices with conditioned media from tumor cells

  • Add anti-TNFSF11 neutralizing antibodies at varying concentrations

  • Measure resorption pit formation via microscopy

  • Quantify released bone degradation products (e.g., CTX-I)

• Animal models with antibody intervention:

  • Establish tumor xenograft models known to induce hypercalcemia

  • Administer anti-TNFSF11 antibodies prophylactically or therapeutically

  • Monitor:

    • Serum calcium levels

    • Bone mineral density

    • Osteoclast numbers (TRAP staining)

    • Tumor burden and osteolytic lesions (μCT imaging)

• Signaling pathway analysis in tumor samples:

  • Perform multiplexed immunofluorescence to co-localize TNFSF11 with:

    • Tumor markers

    • Osteoclast precursor markers

    • Activated signaling molecules (phospho-proteins)

These approaches can help delineate TNFSF11's "important role in enhanced bone-resorption in humoral hypercalcemia of malignancy" and potentially identify therapeutic targets.

What techniques can be used to distinguish between membrane-bound and soluble forms of TNFSF11 in experimental systems?

To differentiate between membrane-bound and soluble TNFSF11:

• Biochemical separation techniques:

  • Ultracentrifugation to separate membrane fractions

  • Sequential protein extraction protocols to isolate membrane-associated versus soluble proteins

  • Follow with western blot analysis using TNFSF11 antibodies to detect:

    • Membrane form (40-45 kDa)

    • Soluble form (31 kDa)

• ELISA-based approaches:

  • Develop sandwich ELISA systems using capture/detector antibody pairs

  • Design assays that specifically detect soluble TNFSF11 in cell culture supernatants or biological fluids

  • Compare levels across different experimental conditions or disease states

• Flow cytometry with differential staining:

  • Surface staining protocols to detect membrane-bound TNFSF11

  • Combine with measurements of soluble TNFSF11 in supernatants

  • Use PE-conjugated antibodies for higher sensitivity

• Metalloprotease inhibition studies:

  • Apply TACE/metalloprotease inhibitors to block cleavage

  • Monitor changes in membrane-bound versus soluble forms

  • Correlate with functional outcomes in osteoclastogenesis assays